Hetero Partners with Gilead Sciences to Expand HIV Treatment and Prevention in 120 LMICs

Strategic Insights -

In a significant move, Health Desk Stock Market Stats Hetero has announced a new partnership with Gilead Sciences Ireland UC to manufacture and distribute lenacapavir in 120 primarily low- and lower-middle-income countries (LMICs). This collaboration aims to broaden access to lenacapavir, an innovative HIV treatment used in combination with other antiretrovirals, and support efforts to prevent HIV through pre-exposure prophylaxis (PrEP). The partnership marks a significant step in expanding access to life-saving treatments for heavily treatment-experienced patients with multi-drug-resistant HIV and offers a promising option for HIV prevention in underserved regions.

Key Takeaways:

  • The partnership between Hetero and Gilead Sciences Ireland UC will enable the manufacturing and distribution of lenacapavir in 120 LMICs, primarily in Africa and India.
  • Lenacapavir is an innovative HIV treatment used in combination with other antiretrovirals, and its approval marks a significant step in expanding access to life-saving treatments for heavily treatment-experienced patients with multi-drug-resistant HIV.
  • The use of lenacapavir for the prevention of HIV is investigational and is not approved anywhere globally.
  • Hetero has been at the forefront of the global fight against HIV/AIDS for over three decades, pioneering affordable, life-saving treatments where the need is greatest.
  • Hetero has over 30 combinations addressing nearly 40% of the global HIV/AIDS population, and the company has been a cornerstone of HIV/AIDS care in Africa, India, and other LMICs.
  • The partnership will leverage Hetero's strong research focus, unparalleled manufacturing scale, and distribution expertise to rapidly expand access to lenacapavir in all 120 high-incidence, resource-limited countries.
  • Gilead Sciences has announced promising results from a pivotal Phase 3 clinical trial demonstrating that lenacapavir reduced HIV infections by 96% compared to the background HIV incidence.

Statistics:

  • 120 LMICs will benefit from the partnership, primarily in Africa and India.
  • 40% of the global HIV/AIDS population is addressed by Hetero's over 30 combinations.
  • 96% reduction in HIV infections was demonstrated in a pivotal Phase 3 clinical trial.
  • Lenacapavir is expected to be administered every six months via a subcutaneous injection, following an initial oral loading dose.
  • The European Union approved lenacapavir for use in HIV-positive adults with multi-drug resistance in August 2022, and the U.S. FDA approved it in December 2022.

Sources:

  • "Hetero on Wednesday announced a new partnership with Gilead Sciences Ireland UC to manufacture and distribute lenacapavir in 120 primarily low- and lower-middle-income countries (LMICs)." - Health Desk Stock Market Stats
  • "This collaboration marks a significant step in expanding access to life-saving treatments for heavily treatment-experienced patients with multi-drug-resistant HIV and offers a promising option for HIV prevention in underserved regions." - Health Desk Stock Market Stats
  • "This partnership with Gilead Sciences strengthens our resolve to push the boundaries of HIV prevention and treatment." - Dr. Vamsi Krishna Bandi, Managing Director of Hetero Group of Companies
  • "Earlier this month, Gilead announced promising results from a pivotal Phase 3 clinical trial." - Health Desk Stock Market Stats
  • "Lenacapavir was approved for use in HIV-positive adults with multi-drug resistance by the European Union in August 2022 and received U.S. FDA approval in December 2022." - Copyright 2024 IE Online Media Services Pvt. Ltd., distributed by Contify.com